HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Cosmetics Funding ‘Inadequate’ – Appropriators Propose $4m Increase

Executive Summary

Proposing $4m bump in FY 2020 for Office of Cosmetics and Colors, House appropriators are "concerned that FDA’s current authority and resources to oversee cosmetics and personal care products are inadequate to properly ensure the safety of cosmetics products.”

You may also be interested in...

House Appropriators' Report Tracks With FDA Concern About CBD Supplements

House Appropriators expect FDA to assert commitment to identifying lawful regulatory pathways for CBD food and supplements if those pathways are consistent with protection of public health. Committee also expresses concern over proliferation of CBD supplements and foods in violation of FDA regulations.

Claire’s Caves, Recalls Makeup Products Following FDA’s Asbestos Finding

The jewelry and cosmetics retailer announced March 11 that it is voluntarily recalling selected lots of three makeup products due to the “possible presence of asbestos fibers.” FDA issued a safety alert the previous week that has made Claire’s the latest poster child for cosmetics regulatory reform.

FDA Determined To Update Cosmetics Regs After Claire’s Refuses To Recall Asbestos-Tainted Makeup

The agency issued a safety alert March 5 advising consumers to avoid three makeup products sold – at least previously – in Claire’s stores, which cater to girls and young women. The situation throws into relief the limitations of the current regulatory framework for cosmetics, which FDA is committed to modernizing while exploring steps to improve oversight using existing tools.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts